High probability of restarting small- and medium-scale tanks in September, but large-scale tank ramp-up and order shortfalls continue to reduce visibility into FY2027 breakeven

Overview

The report summarizes key points from a roundtable between J.P. Morgan and FUJIFILM management regarding the bio CDMO business, focusing on the restart timeline following the shutdown of the North Carolina small- and medium-scale tank facility, the ramp-up of the North Carolina large-scale tank project, order trends across tank sizes, and the FY2027 earnings outlook. The report views the FDA's disposition and the anticipated restart as positive developments, but considers the production cadence of large-scale tanks and early-stage project orders the main uncertainties surrounding FY2027 breakeven.

Core views

The roundtable addressed four issues revealed when 1QFY2026 results were announced: the unexpected shutdown of the North Carolina small- and medium-scale tank facility, the delayed ramp-up of a specific North Carolina large-scale tank project, changes in orders across tank sizes, and the FY2027 outlook. The report's overall assessment is that regulatory obstacles to restarting small- and medium-scale tanks have eased substantially, but the large-scale tank manufacturing cycle is still being improved and the timing for reaching the target remains unclear. Short-cycle orders for small- and medium-scale tanks are also below the original assumption, leaving insufficient visibility into FY2027 breakeven. The management structure has shifted from the expansion and construction phase to the execution phase. Over the past three years, division head Toshihisa Iida and former president Lars Petersen advanced network construction across Kojo X, Denmark, the United States, and Toyama, as well as strategy formulation and capital investment. With the Denmark and UK facilities now operational, execution capabilities have become the priority. Maja Pedersen, who previously oversaw on-site operations, became president and COO of FUJIFILM Diosynth Biotechnologies on August 4, while Iida remains head of the bio CDMO division. The new management team plans to improve operational efficiency and strengthen the sales organization. The bio CDMO business's FY2026 loss is expected to widen from the initial estimate of more than ¥350 hundred million to more than ¥700 hundred million. Of the approximately ¥300 hundred million increase versus the original forecast, the North Carolina large-scale tank project accounts for slightly less than ¥100 hundred million, the unexpected shutdown of small- and medium-scale tanks accounts for slightly less than ¥100 hundred million, and insufficient small- and medium-scale tank orders account for slightly more than ¥100 hundred million. This breakdown indicates that the downgrade was not caused by a single regulatory event, but by the combined effects of the shutdown, capacity ramp-up, and order execution. The shutdown of the small- and medium-scale tank facility followed an unannounced FDA inspection of the North Carolina site in the final week of March and the issuance of a Form 483 concerning microbial contamination. The company responded within two weeks and submitted two reports in May. The FDA subsequently requested additional data on trace-microorganism controls and monitoring, prompting the company to halt production to prioritize data preparation and its regulatory response. Following an August 6 meeting, the company obtained VAI status, avoiding OAI and a Warning Letter under the worst-case scenario, while its corrective actions were also accepted. Restarting production is a business decision for the company and does not require FDA approval; management believes a restart in late September is highly likely. The company does not need to complete every item before restarting, but it must demonstrate that it has identified and blocked the root cause and complete remediation according to the committed plan and deadlines. Some actions have already been completed, while the remaining items begin coming due successively from September, and remediation of upstream processes may take longer. Management stated that it had inspected all facilities, taken corrective measures, and confirmed that similar issues would not spread to other locations. However, it also acknowledged that the FDA's expectations for the company have risen and that vigilance cannot be relaxed. The company believes that handling the matter transparently and involving customers has instead strengthened customer relationships, with no risk of customer attrition. Following receipt of VAI status, customers are more confident about project filing timelines, and the related approval processes are still expected to proceed as planned. The small- and medium-scale tank business shows a divergence between strong commercial-product orders and insufficient early-stage projects. Orders reached $3.5 hundred million in 1Q, above the previous pace, mainly driven by antibody commercial-product orders at the UK and Texas facilities. These orders are under multiyear contracts and will gradually convert into revenue as production lines operate and batches are manufactured; they will not all be recognized in the next fiscal year. Conversely, slightly more than ¥100 hundred million of the increase in the loss forecast relates to insufficient process-development and early-stage projects. Such projects have a shorter cycle from order receipt to revenue recognition, but progress across modalities such as antibodies, microbial culture, cell, and gene therapies has generally lagged. Management believes one reason is that sales resources were prioritized for commercial products and large contracts, while another is that although the company excels at the stability required for large projects, it failed to meet early-stage customers' requirements for speed and flexibility. It is therefore strengthening areas including its organization. The pipeline and number of cell and gene projects appear to have bottomed, but have not yet translated sufficiently into orders. Inquiries, orders, and the pipeline for late-stage small- and medium-scale tank projects are improving. The company believes its differentiation lies in its asset footprint and technology: its facilities are close to end markets in Japan, the United States, and Europe, and some customers that used Chinese facilities during Phase 1 to prioritize speed shift to production sites near major markets beginning in the latter part of Phase 2. Its technological advantages include cell lines, culture media, and perfusion culture. Perfusion culture is particularly suitable for bispecific antibody and ADC projects in which cell instability during scale-up becomes a CMC bottleneck. In one confirmed case, an early-stage project from a major pharmaceutical company is undergoing technology transfer to a UK perfusion-culture production line. Early-stage projects account for approximately one-third of annual small- and medium-scale tank revenue, but their strategic and profit significance exceeds their simple revenue contribution. Process development requires scientific personnel, and improving the utilization efficiency of these experts translates more directly into profit. At the same time, continuously securing early-stage projects gives the company exposure to cutting-edge technologies and allows it to build capabilities for launching different technologies; otherwise, it could lose its competitive advantage. The company is restructuring its commercial-product organization and project system and advancing cell-line development and innovation to establish a faster, more flexible execution system suited to long-term growth. For large-scale tanks, the time required to establish the manufacturing process for a specific North Carolina project following technology transfer exceeded expectations because the project uses an unconventional process. The company conducted careful planning and facility modifications in advance, but some issues could not be identified beforehand. A dedicated team has now been established in North Carolina, and work has progressed to the PPQ stage, which verifies using actual equipment, procedures, and conditions whether the commercial manufacturing process can consistently and reproducibly produce qualified products. The company will cautiously shorten batch intervals while monitoring quality and the number of deviations. Management cited the Denmark facility as a comparison, where all 10 PPQ and technology-transfer projects undertaken after its launch last year proceeded according to plan, and believes the current irregularity mainly reflects the project's process itself rather than a widespread execution issue. The company has an internal target date for reaching the intended production speed, but cannot make a commitment because acceleration must occur gradually under controlled conditions. The issue's impact on FY2026 is slightly less than ¥100 hundred million. Management believes the impact will gradually narrow and that the direction of improvement is clear, but it has not ruled out residual losses and must run more batches before determining their scale. To reduce similar issues, the company plans to begin using around next year a pilot line built in Denmark approximately two years ago, allowing abnormal characteristics to be identified at an intermediate scale between the laboratory and large-scale tanks. It will also extend data, personnel, and experience accumulated in Denmark to other facilities while incorporating external opinions. The company cannot guarantee that such problems will never recur. Large-scale tank orders were approximately $1 hundred million in 1Q, mainly from the Denmark facility. This was below management's expectations and was also insufficiently balanced against the $3.5 hundred million in small- and medium-scale tank orders. Many orders involve late-stage clinical drugs, and customers typically place orders only through the PPQ stage before adding high-volume orders after approval. Consequently, if several contracts within the current approximately $1 hundred million portfolio achieve commercialization and indication expansion, they could develop into significantly larger projects. Management believes these orders, which were discussed several years in advance, have established a solid foundation, although final approval of innovative drugs remains difficult to predict. Regional demand temporarily shifted toward the United States because of tariffs, but with tariff rates now determined, demand has begun returning to Europe. Multiple transactions are progressing in both Denmark and the United States. The planned 2028 start of operations in Denmark remains unchanged for now, and the company discusses progress, volume, and speed with customers approximately every week. For FY2027, management believes the large-scale tank recovery shortfall and insufficient small- and medium-scale tank orders may partly persist, but they are currently difficult to quantify. The key variables are how much North Carolina batch intervals can be shortened, how quickly ramp-up proceeds, and the pace at which short-cycle early-stage project orders accumulate. J.P. Morgan expects visibility into FY2027 earnings to improve gradually beginning with 2Q results as the large-scale tank manufacturing cycle improves and small- and medium-scale tank order conditions become clearer. Another path to breakeven is operational efficiency. Given substantial revenue volatility, Pedersen plans to examine both the revenue and cost sides. The objective is not simply to cut costs, but to follow the Fujifilm Way by sequentially reviewing business systems, streamlining processes, and simplifying job responsibilities, with a particular focus over the coming months on using manufacturing systems and AI for further simplification. The company has already used AI on a small scale to gather audit-preparation data, reducing the number of people involved and improving inspection readiness, but this has not yet translated directly into layoffs. Management's operational challenge is to keep growth in the cost base within 10% when revenue increases by 20%. If AI can reduce work such as the approximately four hours of batch-deviation processing per production tank, existing personnel could support more batches. The company may add resources in areas directly tied to revenue, such as sales, and will not blindly compress costs at the expense of quality and success rates. The investment thesis ultimately depends on whether the bio CDMO business can achieve breakeven in FY2027 as the company expects and generate profit growth thereafter. The report uses average peer valuations for each business in its SOTP valuation, producing an end-December 2026 target price of ¥5,000 based on an overall FY2027E EV/EBITDA multiple of 10.8x. The Healthcare, Electronics, Business Innovations, and Imaging businesses are assigned multiples of 13.7x, 11.0x, 7.8x, and 9.2x, respectively. J.P. Morgan's own FY2027E EV/EBITDA is 10.1x, a 0.7x discount to the valuation, which the report considers commensurate with uncertainty surrounding the bio CDMO outlook. The report forecasts a consolidated EBITDA CAGR of 9.4% from FY2027 to FY2030, including 21.0% for Healthcare, 5.0% for Electronics, 0.1% for Business Innovations, and 1.7% for Imaging. In the SOTP table, consolidated operating profit for FY2026E, FY2027E, and FY2028E is ¥373,600 million, ¥439,600 million, and ¥485,600 million, respectively, while EBITDA is ¥583,600 million, ¥649,600 million, and ¥695,600 million; the corresponding theoretical share prices are ¥4,995, ¥5,376, and ¥5,601.

Analysis framework

The report first uses the management roundtable to verify individually the four issues behind the 1QFY2026 downgrade, then separately analyzes the FDA's disposition and production restart, the order mix across tank sizes, the North Carolina large-scale tank manufacturing cadence, and organizational efficiency reforms, mapping these operating variables to visibility into FY2027 breakeven. For valuation, the report applies peer EV/EBITDA multiples separately to businesses including Healthcare, Electronics, Business Innovations, and Imaging, then aggregates them through SOTP to derive equity value and the target price.

Methodology notes

• Valuation methodologySOTP segment valuation

  Sum-of-the-parts valuation

  The report applies the relevant peer valuation multiples separately to Healthcare, Electronics, Business Innovations, Imaging, and other businesses, then deducts net debt and divides by the share count to derive a theoretical share price reflecting the value of FUJIFILM's diversified business portfolio.

• Valuation methodologyEV/EBITDA valuation

  Peer-company EV/EBITDA multiples

  The report derives its valuation using an overall FY2027E EV/EBITDA multiple of 10.8x and notes that J.P. Morgan's own forecast implies 10.1x, a 0.7x discount; this discount reflects uncertainty surrounding the bio CDMO earnings outlook.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• FUJIFILM Holdings（4901.T）

  The restart, capacity ramp-up, order conversion, and FY2027 breakeven of the bio CDMO business are the core variables affecting the company's valuation and earnings growth described in the report.

  Strengths

  Its global production assets are close to end markets in Japan, the United States, and Europe, and it has capabilities in cell lines, culture media, and perfusion culture; small- and medium-scale tank commercial-product orders are strong, while the late-stage project pipeline is improving.

  Weaknesses

  The special North Carolina large-scale tank project is ramping slowly, execution speed and flexibility for early-stage small- and medium-scale tank projects are insufficient, and the FY2026 bio CDMO loss is expected to widen to more than ¥700 hundred million.

  Comparison

  The SOTP uses peer-company segment valuations, with an overall FY2027E EV/EBITDA multiple of 10.8x, while J.P. Morgan's own forecast implies 10.1x, a 0.7x discount.

  Risks

  FY2027 breakeven could be delayed by slow improvement in the large-scale tank production cadence, insufficient early-stage orders, or higher remediation and operating costs; yen appreciation and stagnating Healthcare growth also represent downside scenarios for the rating and target price.

Key data

• Current price¥3,220August 20, 2026
• Target price¥5,000End-December 2026, rated Overweight
• Expected FY2026 bio CDMO lossMore than ¥700 hundred millionInitial assumption was more than ¥350 hundred million
• Increase in loss forecastApproximately ¥300 hundred millionSlightly less than ¥100 hundred million from the large-scale tank impact, slightly less than ¥100 hundred million from the small- and medium-scale tank shutdown, and slightly more than ¥100 hundred million from insufficient small- and medium-scale tank orders
• Small- and medium-scale tank 1Q orders$3.5 hundred millionMainly multiyear contracts for antibody commercial products at the UK and Texas facilities
• Large-scale tank 1Q ordersApproximately $1 hundred millionMainly from the Denmark facility; management considers the scale insufficient and inadequately balanced against small- and medium-scale tank orders
• Early-stage project revenue contributionApproximately one-thirdRefers to annual small- and medium-scale tank revenue, with the remainder coming from late-stage and commercial products
• FY2026 impact of large-scale tank delaySlightly less than ¥100 hundred millionExpected to narrow gradually, but residual impact cannot yet be ruled out
• Efficiency management targetKeep cost-base growth within 10% when revenue grows by 20%The objective is to convert the gap between revenue and cost growth into profit
• Batch-deviation processing timeApproximately 4 hours per production tankManagement believes that if AI can reduce this work, existing personnel can support more batches
• Overall FY2027E valuation multiple10.8x EV/EBITDAJ.P. Morgan's own FY2027E EV/EBITDA is 10.1x, a 0.7x discount
• FY2027E segment valuation multiplesHealthcare 13.7x, Electronics 11.0x, Business Innovations 7.8x, Imaging 9.2xBased on average peer valuations as of June 22
• FY2027—FY2030 EBITDA CAGRConsolidated 9.4%Healthcare 21.0%, Electronics 5.0%, Business Innovations 0.1%, Imaging 1.7%
• Consolidated operating profit forecastFY2026E ¥373,600 million; FY2027E ¥439,600 million; FY2028E ¥485,600 millionSOTP valuation table forecast
• Consolidated EBITDA forecastFY2026E ¥583,600 million; FY2027E ¥649,600 million; FY2028E ¥695,600 millionSOTP valuation table forecast
• FY2027E SOTP equity value¥6,471,342 millionTheoretical enterprise value ¥7,047,405 million, net debt ¥576,063 million, and 1,204 million shares outstanding
• SOTP theoretical share priceFY2026E ¥4,995; FY2027E ¥5,376; FY2028E ¥5,601The report's official target price is ¥5,000

Impact & implications

VAI status and the anticipated production restart reduce the near-term regulatory tail risk at the small- and medium-scale tank facility, while commercial-product orders and the late-stage project pipeline also indicate that the underlying demand base remains intact. However, the FY2027 earnings recovery depends not only on restarting production, but also on whether North Carolina large-scale tanks can safely shorten batch intervals, whether early-stage projects can convert into short-cycle orders, and whether efficiency reforms can control costs while maintaining quality. The report therefore retains its positive rating but applies a 0.7x EV/EBITDA discount in its valuation to reflect uncertainty surrounding bio CDMO.

Risks

• If North Carolina large-scale tank batch intervals cannot be shortened as planned, the FY2026 impact may leave residual losses and weaken visibility into FY2027 breakeven.
• If order conversion from early-stage small- and medium-scale tank projects remains insufficient, short-cycle revenue and scientific personnel utilization may fall below management's targets.
• FDA remediation must be completed by the committed deadlines, upstream-process remediation may take longer, and the company cannot guarantee that other manufacturing issues will never recur.
• Adding resources to comprehensively address FDA matters or strengthen sales could increase costs, although management stated that it will examine both the revenue and cost sides.
• Downside scenarios for the rating and target price identified in the report include a shift toward yen appreciation and stagnating Healthcare growth.

What to watch

• Whether the North Carolina small- and medium-scale tank facility restarts in late September as management expects and completes the remaining FDA corrective actions on schedule.
• PPQ progress for the North Carolina large-scale tank project, the speed of shortening batch intervals, the number of deviations, and the timing for reaching the target production speed.
• Whether visibility into FY2027 earnings improves beginning in 2Q as the manufacturing cycle improves.
• Whether the early-stage and late-stage small- and medium-scale tank project pipelines convert into short-cycle orders.
• Progress on large-scale tank transactions in Denmark and the United States, and whether the planned 2028 launch of the Denmark facility remains unchanged.
• Whether operating processes, manufacturing systems, and AI can keep growth in the cost base within 10% when revenue grows by 20%.
• Target-price scenario factors identified in the report, including Healthcare growth, MFP earnings improvement, expansion of share repurchases, and exchange-rate movements.